

# **ADIPOKINE LEVELS AS A PREDICTOR OF LIVER INJURY IN NON-ALCOHOLIC FATTY LIVER DISEASE**

**Thesis**

*Submitted for partial Fulfillment of The MD Degree In Internal  
medicine*

**By**

**Shrook Mohammed Moussa**

*(M. B., B.Ch) (M.Sc)*

*Faculty of Medicine, Cairo University*

**Under Supervision of**

**Prof. DR. Khadega Ramadan EL-Ashmawy**

*Professor of Internal Medicine*

*Faculty of Medicine- Cairo University*

**Prof. Dr. Mona Ahmed Amin**

*Professor of Internal Medicine*

*Faculty of Medicine- Cairo University*

**Prof. Dr. Olfat Shaker**

*Professor of Medical Biochemistry*

*Faculty of Medicine- Cairo University*

**Faculty of Medicine**

**Cairo University**

**2013**



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ  
الْحَكِيمُ

صدق الله العظيم  
سورة البقرة الآية (32)



## *Acknowledgement*

*First and foremost, thanks to “GOD” the most beneficent and merciful for his help during this work as a little part of his generous help throughout my life.*

*I would like to thank my **Prof. Khadiga Elashmawy**, professor of internal medicine, Faculty of Medicine Cairo University, who has been of great intellectual support; she gave me of her time and helped me go through the hard way with constant encouragement and influential discussions. I am so grateful for her valuable guidance and support.*

*I would like to express my sincere gratitude to my **Prof. Mona Amin**, professor of internal medicine, Faculty of Medicine Cairo University, for her continuous support, patience, motivation, enthusiasm, and immense knowledge. Her guidance helped me in all the time of research and writing of this thesis.*

*My great appreciation and sincere thanks to **Prof. Olfat Shaker**, Professor of Medical biochemistry, Cairo University, for her continuous guidance and valuable advice for enriching this work. I appreciate her great support for me, which has given me a powerful push helping this study to be established.*

*Many thanks to the staff members of internal medicine department and my colleagues for their support.*

*I would like to thank my family, especially my mother and father for always believing in me, for their continuous love and their supports in my decisions.*

*Last but not least important, I owe more than thanks to my husband, who stood by me, and gave me much of his time and support.*

# *List of Contents*

	<b>Pages</b>
<b>List of Abbreviation</b>	
<b>List of Tables</b>	
<b>List of Figures</b>	
<b>Introduction</b>	<b>1</b>
<b>Aim of the Study</b>	<b>3</b>
<b>Review of literature</b>	<b>4</b>
<b>Chapter (1):</b> <ul style="list-style-type: none"><li>• <b>Non Alcoholic Fatty Liver Disease</b></li></ul>	<b>4</b>
<b>Chapter (2):</b> <ul style="list-style-type: none"><li>• <b>Adiponectin And Its Role In Pathogenesis And Treatment Of Non-Alcoholic Fatty Liver</b></li></ul>	<b>72</b>
<b>Chapter (3):</b> <ul style="list-style-type: none"><li>• <b>Leptin And Its Role In Pathogenesis And Treatment Of Non-Alcoholic Fatty Liver</b></li></ul>	<b>105</b>
<b>Patients and Methods</b>	<b>143</b>
<b>Results</b>	<b>152</b>
<b>Discussion</b>	<b>189</b>
<b>Summary and Conclusions</b>	<b>204</b>
<b>References</b>	<b>207</b>
<b>Arabic summary</b>	<b>259</b>

## *List Abbreviations*

ACC	Acetyl Coenzyme A carboxylase
ACE	Angiotensin-converting enzyme
ACOX	Acyl-CoA oxidase
ACP	Acylation stimulating protein
ADP	Adenosine diphosphate
AGRP	Agouti-related peptide
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
AMPK	5' AMP-activated protein kinase
AOX1	Aldehyde oxidase 1
ARB	Angiotensin II type 1 receptor blocker
AST	Aspartate aminotransferase
AT-I	Angiotensin II type 1
ATP	Adenosine triphosphate
BBB	Blood brain barrier
BMI	Body mass index
CAMP	Cyclic adenosine monophosphate
CK-18	Cytokeratin-18
CPT-1	Carnitine palmitoyl transferase 1
CRP	C-reactive protein
CT	<i>Computed Tomography</i>
CTGF	Connective tissue growth factor
DNL	De novo lipogenesis
DPI	Doppler perfusion index
ECM	Extracellular matrix (ECM)
EGP	Endogenous glucose production
ER	Endoplasmic reticulum
ET-1	Endothelin-1
FAS	Fatty acid synthase
FFA	Free fatty acids
GGT	Gamma-glutamyltransferase
GLP-1	Glucagon-like peptide 1
GLUT4	Glucose transporter 4
GNG	Gluconeogenesis
GPAT	Glycerol-3-phosphate acyltransferase (GPAT)
GSH-Px	Glutathione peroxidase
GSK3	Glycogen synthase kinase 3
H2O2	Hydrogen peroxide
HCC	Hepatocellular carcinoma

HMG CoA	Hepatic 3-hydroxyl-3-methylglutaryl coenzyme A
HMW	High-molecular weight
HNE	4-hydroxynonenal
HOMA	Homeostasis model assessment
HSCs	Hepatic stellate cells
HTGC	Hepatic triglyceride content
Hus	Hounsfield units
ICV	Intracerebroventricular
IGFBP2	IGF binding protein-2
IL-1	Interleukin -1
L-6	Interleukin-6
IR	Insulin resistance
IRS	Insulin receptor substrates
JAK2	Janus kinase 2
KATP	ATP-sensitive potassium channels
KCs	Kupffer cells
LCAS	Long chain acyl-CoA synthetase .
LDL-C	Low-density lipoprotein cholesterol
LHA	Lateral hypothalamic area
MAPK	Mitogen activated protein kinase
MCH	Melanin-concentrating hormone
MDA	malondialdehyde
MRI	Magnetic Resonance Imaging
MRS	Proton Magnetic Resonance Spectroscopy
NAFL	nonalcoholic fatty liver
NAFLD	Non-alcoholic fatty liver disease
NAS	NAFLD Activity Score
NASH	Non-alcoholic steatohepatitis
NFκB	Nuclear factor-kappaB
NPC1L1	Niemann-Pick type C protein
NPY	Neuropeptide Y
PAI-1	Plasminogen activator -1
PDGF	Platelet-derived growth factor
PGC-1 α	PPARγ coactivator-1 α
PI3K	Phosphoinositide 3-kinase
PKC	Protein kinase C
PPAR-γ	Peroxisome proliferator activator receptor gamma
PTP1B	Protein tyrosine phosphatase 1B
PTX3	Plasma pentraxin 3
PVN	Paraventricular nucleus.
ROS	Reactive oxygen species

<b>SAMe</b>	<b>S-adenosylmethionine</b>
<b>SAT</b>	<b>Subcutaneous adipose tissue</b>
<b>SECs</b>	<b>Sinusoidal endothelial cells</b>
<b>SNPs</b>	<b>Single nucleotide polymorphisms</b>
<b>SNS</b>	<b>sympathetic nervous system</b>
<b>SOCS-3</b>	<b>Suppressor of cytokine signaling-3</b>
<b>SPEA</b>	<b>Serum prolidase enzyme activity</b>
<b>SREBP-1c</b>	<b>transcription factor sterol regulatory element binding protein-1c</b>
<b>STAT3</b>	<b>Signal transducer and activator of transcription 3</b>
<b>T2DM</b>	<b>Type 2 diabetes mellitus</b>
<b>TGFb-1</b>	<b>Transforming growth factor beta-1</b>
<b>TGF-β</b>	<b>Transforming growth factor beta</b>
<b>TNF α</b>	<b>Tumour necrosis factor α</b>
<b>TRX</b>	<b>Thioredoxin</b>
<b>TZDs</b>	<b>Thiazolidinediones</b>
<b>UDCA</b>	<b>Ursodeoxycholic acid</b>
<b>VAT</b>	<b>Visceral adipose tissue</b>
<b>VEGF</b>	<b>Vascular endothelial growth factor</b>
<b>VLDL</b>	<b>Very low density lipoprotein</b>
<b>WAT</b>	<b>White adipose tissue</b>
<b>α-MSH</b>	<b>α-melanocyte stimulating hormone</b>
<b>11b-HSD1</b>	<b>11b-hydroxysteroid dehydrogenase type 1</b>
<b>5αR</b>	<b>5-α reductase</b>

## *Lists of Tables*

Table	Title	Page
<b>Review</b>		
I	Metabolic Syndrome Criteria	5
II	Common Causes of Secondary Hepatic Steatosis.	7
III	Nonalcoholic Fatty Liver Disease and Related Definitions	8
IV	Risk factors for the presence of NAFLD	11
V	Typical lobular changes occurring in steatohepatitis	43
VIa	Histological grading and staging of non-alcoholic steatohepatitis /fibrosis	47
VIb	NAFLD Activity Score (NAS).	49
VIc	Correlation between total NAFLD activity scores and an overall histological diagnosis of steatohepatitis.	50
VII	Physiological and pathophysiological conditions and treatment modalities associated with either decrease or increase in plasma adiponectin levels	84
VIII	Suggested treatment strategies for NAFLD based on adiponectin action	100
IX	Regulators of circulating leptin levels.	114
<b>Results</b>		
1a	Comparison of demographic features between patients and controls.	160
1b	Comparison of anthropometric measures between patients and controls.	160
2	Comparison between NAFLD and controls regarding biochemical	161



	profile.	
3	Comparison of serum biomarkers (adiponectin, leptin), A/L and Hs CRP between NAFLD patients group (I) and controls group (II).	163
4a	Comparison between NASH (Group IA) & SS (Group IB) as regard demographic data.	166
4b	Comparison between NASH (Group IA) & SS group (Group IB) as regard anthropometric measures.	166
5	Comparison between NASH (Group IA) & SS (Group IB) as regard biochemical profile.	167
6	Comparison of serum biomarkers (adiponectin, leptin), A/L and HsCRP between NASH (group IA) and SS (group1B).	167
7	Correlation of Adiponectin with other parameters within the studied groups.	169
8	Correlation of Leptin with other parameters within the studied groups.	175
9	Correlation of A/L ratio with other parameters within the studied groups.	176
10	Correlation between hs CRP and different variables within the studied groups.	183
11	Effect of Gender difference in serum leptin and adiponectin among patients.	184
12	Area under the curve (AUC) of the studied serum adiponectin, leptin and A/L in NAFLD patients and controls.	185
13	Area under the curve (AUC) of the studied serum adiponectin, leptin and A/L in NASH group and SS group.	186

## *List of Figures*

Figure	Content	Page
I	The natural history of NAFLD	13
II	Pathogenesis of nonalcoholic stetohepatitis	15
III	Mechanisms of fat accumulation in non-alcoholic steatohepatitis.	16
Iva	Non-alcoholic fatty liver (NAFL).	44
IVb	Non-alcoholic steatohepatitis (NASH).	44
V	Potential pathophysiologic effects of therapies that are under investigation	52
VI	Adiponectin's actions in major tissues and organs	76
VII	<i>The domain structure of Acrp30</i>	77
VIII	Adiponectin can activate AMPK and PPAR $\alpha$ in the liver and skeletal muscle	89
IX	A summary of multiple signaling pathways that mediate the anti-steatotic effects of adiponectin.	90
X	The molecular action of adiponectin in the liver.	97
XI	Adiponectin hypothesis for insulin resistance, metabolic syndrome, and atherosclerosis:	99
XII	Therapeutic strategies upregulating adiponectin or interplaying with adiponectin signalling in non-alcoholic fatty liver disease.	101
XIII	TZDs ameliorate insulin resistance and diabetes by both adiponectin-dependent and independent pathways.	104
XIV	Leptin acts by binding to specific receptors (ObR	112
XV	Direct actions of leptin on tissues that contribute to glucose homeostasis	121
XVI	Centrally mediated actions of leptin on tissues that contribute	122

	to glucose homeostasis	
XVII	Management of caloric excess in non adipose tissues	134
	<b><u>Results</u></b>	
1	Mean ALT and AST levels in NAFLD patients group (I) and controls group (II):	162
2	Mean T. Cholesterol, Triglyceride and LDL levels in NAFLD patients (group I) and controls (group II):	162
3	Mean serum adiponectin concentration in NAFLD patients (group I) and controls (group II)	163
4	Figure ( 4 ): Mean serum leptin concentration in NAFLD patients (group I) and controls (group II)	164
5	Mean A/L in NAFLD patients (group I) and controls (group II);	164
6	Mean HsCRP in NAFLD patients (group I) and controls (group II).	165
7	Mean serum concentration of adiponectin in NASH (group IA) and SS (group IB).	168
8	Mean A/L in NASH (group IA) and SS (group IB)	168
9	Correlation between serum adiponectin and BMI in group IA	170
10	correlation between serum adiponectin and BMI in SS group:	170
11	Correlation between serum adiponectin and BMI in group IC.	171
12	Correlation between serum adiponectin and total cholesterol in NASH group (group IA).	171
13	correlation between serum adiponectin and LDL in NASH group (group IA)	172
14	Correlation between serum adiponectin and total cholesterol in SS group (group IB).	172
15	Correlation between serum adiponectin and LDL in SS group (group IB).	173

16	correlation between seum adiponectin and total cholesterol in (group IC):	173
17	Correlation between serum adiponectin and LDL in (group IC).	174
18	Correlation between serum adiponectin and HDL in group IC.	174
19	correlation between serum adiponectin, serum Leptin and A/L in NASH group (group IA).	177
20	Correlation between serum adiponectin, serum Leptin and A/L in SS group (group IB).	178
21	Correlation between serum adiponectin, serum Leptin and A/L in group IC.	179
22	Correlation between A/L ratio and BMI in NASH group (group IA).	180
23	Correlation between A/L ratio and total cholesterol and LDL in NASH group (group IA).	181
24	Correlation between A/L ratio and HDL in (group IC).	182
25	ROC curve showing the discriminant ability of both Adiponectin &A/L ratio to predict NAFLD.	185
26	ROC curve showing the discriminant ability of Leptin to predict NAFLD.	186
27	ROC curve showing the discriminant ability of both Adiponectin &A/L ratio to predict NASH.	187
28	ROC curve showing the discriminant ability of Leptin to predict NASH.	188



## **INTRODUCTION**

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and covers a wide spectrum of liver pathology-from steatosis alone, through the necroinflammatory disorder of non-alcoholic steatohepatitis (NASH) to cirrhosis and liver cancer (*Raszega-Wyszoirska et al., 2008*). The pathogenesis of NASH is currently thought to involve a multiple-hit process with the first hit being the accumulation of liver fat which is followed by the development of necroinflammation and fibrosis. There is mounting evidence that cytokines secreted from adipose tissue, namely, adipokines, are implicated in the pathogenesis and progression of NAFLD (*Emmanuel et al., 2009*).

Adipose tissue is a massive source of bioactive substances known as adipocytokines, including tumor necrosis factor (TNF)-alpha, resistin, leptin, and adiponectin. Recent advances in medical research view obesity as a chronic low-grade inflammatory state. Hypertrophied adipocytes in obesity release chemokines that induce macrophage accumulation in adipose tissue. Accumulated macrophages in obese adipose tissue produce proinflammatory cytokines and nitric oxide, and these inflammatory changes induce adipocytokine dysregulation. The latter is characterized by a decrease in insulin sensitizing and anti-inflammatory adipocytokines, and an increase in proinflammatory adipocytokines. Adipocytokine dysregulation induces obesity-related metabolic disorders, the so-called metabolic syndrome, which is a cluster of metabolic abnormalities, including diabetes mellitus, hypertension, hyperlipidemia, and NASH (*Kamada et al., 2008*).



Adiponectin is exclusively secreted by adipocytes and is considered as an anti-inflammatory adipokine. It reduces body fat, improves hepatic and peripheral insulin sensitivity, and is inversely associated with body mass index and insulin resistance. In the liver, it prevents lipid accumulation by increasing  $\beta$  oxidation of free fatty acid and/ or by decreasing de novo free fatty acid within hepatocytes (*Emmanuel et al., 2009*).

Leptin is a circulating 16 kDa peptide hormone secreted mainly by adipocytes of white fat tissue. It regulates food intake, body fat, insulin action, thermogenesis, induction of angiogenesis, and modulation of the immune system. Leptin synthesis in adipocytes is regulated by several hormones. Although it is considered as an anorexigenic hormone, its levels are elevated in obesity as a result of resistance to its actions. Leptin is thought to participate in both hits of NASH development. Initially, it contributes to the development of insulin resistance and subsequently steatosis. Furthermore, in the context of liver insult, leptin has a proinflammatory role and is considered to be an essential mediator of liver fibrosis (*Tsochatzis, 2006*).



## **THE AIM OF THIS WORK**

The aim of this work is to determine whether serum levels of adipokines, including the ratio of serum adiponectin to leptin (A/L) levels could predict the severity of liver injury in patients with non-alcoholic fatty liver disease (NAFLD).